Shares of Dare Bioscience Inc (NASDAQ:DARE) gapped up prior to trading on Friday . The stock had previously closed at $1.52, but opened at $1.62. Dare Bioscience shares last traded at $1.66, with a volume of 52,738 shares.
Several research firms recently issued reports on DARE. Maxim Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Dare Bioscience in a report on Tuesday, November 12th. ValuEngine cut Dare Bioscience from a “hold” rating to a “sell” rating in a report on Wednesday.
The company has a fifty day moving average of $0.90 and a 200-day moving average of $0.82.
Dare Bioscience (NASDAQ:DARE) last posted its quarterly earnings data on Thursday, November 14th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.01. On average, research analysts expect that Dare Bioscience Inc will post -0.99 EPS for the current year.
An institutional investor recently raised its position in Dare Bioscience stock. Susquehanna International Group LLP grew its holdings in Dare Bioscience Inc (NASDAQ:DARE) by 293.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,770 shares of the biotechnology company’s stock after purchasing an additional 31,900 shares during the quarter. Susquehanna International Group LLP owned about 0.26% of Dare Bioscience worth $36,000 as of its most recent SEC filing. 4.82% of the stock is owned by institutional investors.
Dare Bioscience Company Profile (NASDAQ:DARE)
Daré Bioscience, Inc, a clinical-stage biopharmaceutical company, focuses on developing and marketing women's reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product candidates include Ovaprene, a non-hormonal monthly contraceptive; and SST-6007, a topical sildenafil cream for female sexual arousal disorder.
Recommended Story: What is meant by a buy rating?
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.